1. Brain integrity is altered by hepatic APOE ε4 in humanized-liver mice
- Author
-
Andreas Giannisis, Kalicharan Patra, Anna K. Edlund, Lur Agirrezabala Nieto, Joan Benedicto-Gras, Simon Moussaud, Andrés de la Rosa, Daniel Twohig, Tore Bengtsson, Yuan Fu, Guojun Bu, Greg Bial, Lander Foquet, Christina Hammarstedt, Stephen Strom, Kristina Kannisto, Jacob Raber, Ewa Ellis, and Henrietta M. Nielsen
- Subjects
Genotype ,Apolipoprotein E4 ,Brain ,Neurodegenerative Diseases ,Mice ,Cellular and Molecular Neuroscience ,Psychiatry and Mental health ,Apolipoproteins E ,Liver ,Mice, Inbred NOD ,Alzheimer Disease ,Animals ,lipids (amino acids, peptides, and proteins) ,Molecular Biology ,Biomarkers - Abstract
Liver-generated plasma apolipoprotein E (apoE) does not enter the brain but nonetheless correlates with Alzheimer’s disease (AD) risk and AD biomarker levels. Carriers of APOEε4, the strongest genetic AD risk factor, exhibit lower plasma apoE and altered brain integrity already at mid-life versus non-APOEε4 carriers. Whether altered plasma liver-derived apoE or specifically an APOEε4 liver phenotype promotes neurodegeneration is unknown. Here we investigated the brains of Fah−/−, Rag2−/−, Il2rg−/− mice on the Non-Obese Diabetic (NOD) background (FRGN) with humanized-livers of an AD risk-associated APOE ε4/ε4 versus an APOE ε2/ε3 genotype. Reduced endogenous mouse apoE levels in the brains of APOE ε4/ε4 liver mice were accompanied by various changes in markers of synaptic integrity, neuroinflammation and insulin signaling. Plasma apoE4 levels were associated with unfavorable changes in several of the assessed markers. These results propose a previously unexplored role of the liver in the APOEε4-associated risk of neurodegenerative disease.
- Published
- 2022